| Name | Title | Contact Details |
|---|
Earli has been funded by Andreessen Horowitz`s Bio Fund, Khosla, Perceptive Advisors, Casdin Capital, Sands Capital, Marc Benioff, Menlo Ventures, ZhenFund. Earli is based in the West Coast`s prime biotech hub in South San Francisco.
Neuralink is developing the capabilities of the brain through technological augmentation. A "neural lace” would be surgically connected to a human brain and allow a user to interact with a computer without the bandwidth challenges that come with current input methods, including keyboards, mice and trackpads. Neuralink will explore how brain interfaces might alleviate the symptoms of dangerous and chronic medical conditions.
Progenitor Cell Therapy, LLC, a cell therapy services company, supports the development and commercialization of cellular therapies. It offers manufacturing practices-compliant services for pre-clinical and clinical development, as well as involves in the commercialization of cellular therapies for clients in the United States and internationally.
IconOVir Bio is a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer. Our proprietary oncolytic virus platform is based on technology developed by scientific founder Clodagh O`Shea, Ph.D., of the Salk Institute. It is designed to address key limitations of first- and second-generation oncolytic viruses.
Libra Therapeutics is focused on developing novel disease-modifying therapeutics that can restore the cellular balance disrupted in neurodegenerative diseases.